The US Food and Drug Association has approved the interleukin-23 inhibitor risankizumab for the treatment of adults with moderate-to-severe Crohn disease.
The US Food and Drug Association has approved the interleukin-23 inhibitor risankizumab for the treatment of adults with moderate-to-severe Crohn disease.
Tumor necrosis factor inhibitors adalimumab and infliximab achieved significantly higher rates of 1-year endoscopic healing of Crohn disease than vedolizumab or ustekinumab in a new analysis.
Tumor necrosis factor inhibitors adalimumab and infliximab achieved significantly higher rates of 1-year endoscopic healing of Crohn disease than vedolizumab or ustekinumab in a new analysis.
Patients with inflammatory bowel disease have higher rates of depression and anxiety, yet fail to complete adequate treatment with antidepressants, investigators found.
Patients with inflammatory bowel disease have higher rates of depression and anxiety, yet fail to complete adequate treatment with antidepressants, investigators found.
A new-user study of older patients with inflammatory bowel disease sought to fill knowledge gaps related to the comparative safety and efficacy of vedolizumab and tumor necrosis factor inhibitors among these patients.
A new-user study of older patients with inflammatory bowel disease sought to fill knowledge gaps related to the comparative safety and efficacy of vedolizumab and tumor necrosis factor inhibitors among these patients.
Pediatric patients with inflammatory bowel disease treated with the interleukin 12/23 inhibitor had more than twice the rate of resolution of skin reactions as those who continued on anti-tumor necrosis factor therapy.
Pediatric patients with inflammatory bowel disease treated with the interleukin 12/23 inhibitor had more than twice the rate of resolution of skin reactions as those who continued on anti-tumor necrosis factor therapy.
Researchers conducting a meta-analysis of studies found an increased rate of cancer among patients with pediatric-onset IBD; however, the overall incidence rate of cancer in this population is low.
Researchers conducting a meta-analysis of studies found an increased rate of cancer among patients with pediatric-onset IBD; however, the overall incidence rate of cancer in this population is low.
Researchers compared results from randomized clinical trials to determine if men and women have significant differences in response to anti-tumor necrosis factor therapies for ulcerative colitis.
Researchers compared results from randomized clinical trials to determine if men and women have significant differences in response to anti-tumor necrosis factor therapies for ulcerative colitis.
Large retrospective study finds patients with Crohn disease have higher risk for chronic obstructive pulmonary disease, while those with ulcerative colitis have more pulmonary vasculitis.
Large retrospective study finds patients with Crohn disease have higher risk for chronic obstructive pulmonary disease, while those with ulcerative colitis have more pulmonary vasculitis.
Most concomitant medications do not affect the efficacy or safety of advanced therapies in ulcerative colitis clinical trials, according to a recent study.
Most concomitant medications do not affect the efficacy or safety of advanced therapies in ulcerative colitis clinical trials, according to a recent study.
Investigators found patients typically preferred intestinal ultrasound for diagnosis and monitoring of Crohn’s disease, while magnetic resonance enterography may be better for diagnosing relapse.
Investigators found patients typically preferred intestinal ultrasound for diagnosis and monitoring of Crohn’s disease, while magnetic resonance enterography may be better for diagnosing relapse.
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
While infliximab proved safe and effective for inducing remission in acute severe ulcerative colitis, higher doses and varied induction strategies showed no significant change in response.
Researchers at the University of Chicago recommend using the EHI with another modality to accurately identify inflammation among patients with Crohn’s disease.
Researchers at the University of Chicago recommend using the EHI with another modality to accurately identify inflammation among patients with Crohn’s disease.
Risk of rescue scores that include several clinical, laboratory, and endoscopic variables may help improve outcomes in patients with acute severe ulcerative colitis.
Risk of rescue scores that include several clinical, laboratory, and endoscopic variables may help improve outcomes in patients with acute severe ulcerative colitis.
Dr Long reviews her presentation from the AIBD regional meeting on using comparative effectiveness data to choose from among the growing number of therapies for treating ulcerative colitis.
Dr Long reviews her presentation from the AIBD regional meeting on using comparative effectiveness data to choose from among the growing number of therapies for treating ulcerative colitis.
Dr Raymond Cross hosts Drs James Lewis and Laura Raffals in a discussion of SPARC, a study of adults with inflammatory bowel disease in which patients are followed prospectively to collect data about to allow prediction of disease course and...
Dr Raymond Cross hosts Drs James Lewis and Laura Raffals in a discussion of SPARC, a study of adults with inflammatory bowel disease in which patients are followed prospectively to collect data about to allow prediction of disease course and...
Dr Caldera, from the University of Wisconsin School of Medicine, provides an overview of the risks of respiratory syncytial virus to older adults, including patients with IBD, and the importance of ensuring patients receive this vaccine along...
Dr Caldera, from the University of Wisconsin School of Medicine, provides an overview of the risks of respiratory syncytial virus to older adults, including patients with IBD, and the importance of ensuring patients receive this vaccine along...
IBD Drive Time Hosts Millie Long, MD, and Raymond Cross, MD, discuss new recommendations for managing inflammatory bowel disease among pregnant patients or those wanting to conceive, resulting from updates to the landmark PIANO study.
IBD Drive Time Hosts Millie Long, MD, and Raymond Cross, MD, discuss new recommendations for managing inflammatory bowel disease among pregnant patients or those wanting to conceive, resulting from updates to the landmark PIANO study.
Dr David Hudesman of NYU-Langone Health joins IBD Drive Time host Dr Raymond Cross to talk about how inflammatory bowel disease affects work productivity and social activities.
Dr David Hudesman of NYU-Langone Health joins IBD Drive Time host Dr Raymond Cross to talk about how inflammatory bowel disease affects work productivity and social activities.
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Erin Forster of the Medical University of South Carolina joins IBD Drive Time hosts Dr Millie Long and Dr Raymond Cross to review results of the trials for risankizumab in ulcerative colitis and discuss its positioning in treatment.
Dr Jana Al Hashash from Mayo Clinic—Florida offers guidance on how diet can affect IBD and the best approaches to maintaining adequate nutrition, along with hosts Millie Long, MD, and Raymond Cross, MD.
Dr Jana Al Hashash from Mayo Clinic—Florida offers guidance on how diet can affect IBD and the best approaches to maintaining adequate nutrition, along with hosts Millie Long, MD, and Raymond Cross, MD.
Dr Bhat reports on the recent systematic review and RAND consensus process to define the role of the clinical pharmacist in caring for patients with inflammatory bowel disease.
Dr Bhat reports on the recent systematic review and RAND consensus process to define the role of the clinical pharmacist in caring for patients with inflammatory bowel disease.
In part 2 of this podcast, cohost Dr Millie Long discusses her picks for the "Best of DDW" on inflammatory bowel disease with her cohost, Dr Ray Cross.
In part 2 of this podcast, cohost Dr Millie Long discusses her picks for the "Best of DDW" on inflammatory bowel disease with her cohost, Dr Ray Cross.
In the first episode of this two-part series, Dr Raymond Cross of Mercy Medical Center reviews his top picks for the best abstracts on inflammatory bowel disease presented at this year's Digestive Disease Week with cohost Dr Millie Long of...
In the first episode of this two-part series, Dr Raymond Cross of Mercy Medical Center reviews his top picks for the best abstracts on inflammatory bowel disease presented at this year's Digestive Disease Week with cohost Dr Millie Long of...